주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
European Society of Cardiology (ESC) Congress 2025
29 August - 01 September, 2025, Spain
Three-month DAPT post MI may suffice
2025-10-01
Although guidelines recommend 12 months of dual antiplatelet therapy (DAPT) following a
heart attack
, results from the DUAL-ACS* trial appear to show otherwise.
Olezarsen lowers triglycerides in patients with moderate HTG, high CV risk
2025-10-01
Treatment with olezarsen 50 or 80 mg
significantly reduced triglyceride levels
in patients with
moderate hypertriglyceridaemia (HTG) and elevated cardiovascular (CV) risk compared with placebo,
according to the Essence-TIMI 73b trial presented at ESC 2025.
Add-on baxdrostat shows promise for hard-to-control BP
2025-10-01
In the phase III BaxHTN trial, the highly selective and potent aldosterone synthase inhibitor baxdrostat efficiently controls blood pressure (BP) when added to background antihypertensive therapy for the treatment of uncontrolled or treatment-resistant
hypertension
(HTN).
Inclisiran-based strategy achieves LDL-C goals in patients at high CV risk
2025-10-01
Treatment with inclisiran, on top of individually optimized lipid-lowering therapy (ioLLT), resulted in the achievement of guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals among patients with hypercholesterolaemia at high or very high risk of cardiovascular (CV) events, according to the VICTORION-Difference trial presented at
ESC
2025.
Semaglutide, dulaglutide help prevent cognitive decline in HF patients
2025-10-01
Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with
heart failure
(HF), as shown by the results of a retrospective cohort study using real-world data.
Amlodipine-telmisartan-chlorthalidone combo promises better BP-lowering effect
2025-10-01
A low-dose combination therapy, AD-209, that includes telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 6.25 mg demonstrates efficacy in lowering
high blood pressure
(BP) when compared with telmisartan alone in patients with essential hypertension, reports a study presented at ESC 2025.
Remote AF screening with ECG patch nudges up diagnosis numbers
2025-10-01
A remote screening method using a wearable ECG patch yields a modest increase in atrial fibrillation (AF) diagnoses among older adults at risk of stroke, according to the AMALFI trial.
ALONE-AF: Safe to stop anticoagulant therapy after AF ablation for recurrence-free patients
2025-10-01
For individuals without documented recurrence for at least a year following catheter ablation for atrial fibrillation (AF), discontinuing oral anticoagulant therapy results in more favourable outcomes than when continued, according to the ALONE-AF trial.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
